Roivant Sciences (NASDAQ:ROIV) Hits New 1-Year Low – What’s Next?

Roivant Sciences Ltd. (NASDAQ:ROIV) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $8.73 and last traded at $8.84, with a volume of 1180879 shares. The stock had previously closed at $9.46.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Roivant Sciences Stock Performance

The firm has a market cap of $6.53 billion, a P/E ratio of -61.06 and a beta of 1.25. The company has a 50 day moving average of $10.62 and a 200 day moving average of $11.32.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In other news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction on Monday, January 13th. The shares were acquired at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 1,395,541 shares of company stock valued at $15,028,538. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP increased its position in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares in the last quarter. State Street Corp raised its holdings in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares during the last quarter. XTX Topco Ltd grew its holdings in Roivant Sciences by 116.3% during the 3rd quarter. XTX Topco Ltd now owns 55,500 shares of the company’s stock worth $640,000 after acquiring an additional 29,842 shares during the last quarter. Pier Capital LLC raised its stake in shares of Roivant Sciences by 1.1% in the third quarter. Pier Capital LLC now owns 429,908 shares of the company’s stock worth $4,961,000 after acquiring an additional 4,821 shares during the last quarter. Finally, Raab & Moskowitz Asset Management LLC acquired a new position in shares of Roivant Sciences during the third quarter worth approximately $127,000. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.